How to Fill Out Form FDA 1572

Form FDA 1572 at a glance

What it is: Form FDA 1572 is the Statement of Investigator (Title 21, Code of Federal Regulations (CFR) Part 312) of the Food and Drug Administration.

Where and when to file: Forward the completed form and other documents being provided to the sponsor.

No investigator may participate in an investigation until he/she provides the sponsor with a completed, signed Statement of Investigator, Form FDA 1572 (21 CFR 312.53(c)).

A filled-in Form FDA 1572 example: a Phase 1 investigator signs the form

Form FDA 1572 example filled out, example: a Phase 1 investigator signs the form
Jane Sample is an investigator who completes Form FDA 1572. She provides a curriculum vitae for a Phase 1 study with no subinvestigators. The picture shows the signed form, and all its values are invented.

How to fill out Form FDA 1572, box by box

Box 1, name and address of investigator

In box 1, enter the Name of Clinical Investigator, Address 1, Address 2, City, State/Province/Region, Country and ZIP or Postal Code.

Box 2, curriculum vitae or other statement of qualifications

Select one of the following: Curriculum Vitae or Other Statement of Qualifications.

Provide curriculum vitae or other statement of qualifications as described in Section 2.

Boxes 3 to 5, facilities and review board

In box 3, enter the Name of Medical School, Hospital, or Other Research Facility where the clinical investigation(s) will be conducted, with its Address 1, Address 2, City, State/Province/Region, Country and ZIP or Postal Code.

In box 4, enter the Name of Clinical Laboratory Facility to be used in the study, with its Address 1, Address 2, City, State/Province/Region, Country and ZIP or Postal Code.

In box 5, enter the Name of IRB, the institutional review board (IRB) that is responsible for review and approval of the study(ies), with its Address 1, Address 2, City, State/Province/Region, Country and ZIP or Postal Code.

Box 6, names of subinvestigators

In box 6, enter the names of subinvestigators. If not applicable, enter “None”.

Box 7, protocol name and code number

In box 7, enter the name and code number, if any, of the protocol(s) in the IND for the study(ies) to be conducted by the investigator.

Box 8, clinical protocol information

Select one of the following. For Phase 1 investigations, a general outline of the planned investigation including the estimated duration of the study and the maximum number of subjects that will be involved.

For Phase 2 or 3 investigations, an outline of the study protocol including an approximation of the number of subjects to be treated with the drug and the number to be employed as controls, if any; the clinical uses to be investigated; characteristics of subjects by age, sex, and condition; the kind of clinical observations and laboratory tests to be conducted; the estimated duration of the study; and copies or a description of case report forms to be used.

Provide protocol outline as described in Section 8.

Box 9, commitments

I agree to conduct the study(ies) in accordance with the relevant, current protocol(s) and will only make changes in a protocol after notifying the sponsor, except when necessary to protect the safety, rights, or welfare of subjects.

I agree to personally conduct or supervise the described investigation(s).

I agree to inform any patients, or any persons used as controls, that the drugs are being used for investigational purposes and I will ensure that the requirements relating to obtaining informed consent in 21 CFR Part 50 and institutional review board (IRB) review and approval in 21 CFR Part 56 are met.

I agree to report to the sponsor adverse experiences that occur in the course of the investigation(s) in accordance with 21 CFR 312.64.

I have read and understand the information in the investigator's brochure, including the potential risks and side effects of the drug.

I agree to ensure that all associates, colleagues, and employees assisting in the conduct of the study(ies) are informed about their obligations in meeting the commitments in this section.

I agree to maintain adequate and accurate records in accordance with 21 CFR 312.62 and to make those records available for inspection in accordance with 21 CFR 312.68.

I will ensure that an IRB that complies with the requirements of 21 CFR Part 56 will be responsible for the initial and continuing review and approval of the clinical investigation.

I also agree to promptly report to the IRB all changes in the research activity and all unanticipated problems involving risks to human subjects or others.

Additionally, I will not make any changes in the research without IRB approval, except where necessary to eliminate apparent immediate hazards to human subjects.

I agree to comply with all other requirements regarding the obligations of clinical investigators and all other pertinent requirements in 21 CFR Part 312.

Boxes 10 and 11, date and signature

Sign and date: enter the DATE (mm/dd/yyyy) in box 10 and the SIGNATURE OF INVESTIGATOR in box 11.

A willfully false statement is a criminal offense. U.S.C. Title 18, Sec. 1001.

More rules for Form FDA 1572

Complete all sections. Provide a separate page if additional space is needed.

Common questions about Form FDA 1572

What is form 1572 in clinical research?

Form FDA 1572 is the Statement of Investigator (Title 21, Code of Federal Regulations (CFR) Part 312) of the Food and Drug Administration. The sponsor will incorporate this information along with other technical data into an Investigational New Drug Application (IND).

Where do I file it?

Forward the completed form and other documents being provided to the sponsor. Investigators should not send this form directly to the Food and Drug Administration.

Sources

[1] Form FDA 1572 (4/25), Statement of Investigator, Food and Drug Administration (the Official source link on this page).

Form FDA 1572 PDF Details

Forward the completed form and other documents being provided to the sponsor. Investigators should not send this form directly to the Food and Drug Administration.

Sponsor: the sponsor will incorporate this information along with other technical data into an Investigational New Drug Application (IND).

Qualifications: provide curriculum vitae or other statement of qualifications as described in Section 2.

Protocol: provide protocol outline as described in Section 8.

Space: provide a separate page if additional space is needed.

Subinvestigators: if not applicable, enter "None".

Signature: a willfully false statement is a criminal offense.

QuestionAnswer
Form NameForm FDA 1572
Form Length2 pages
Fillable?Yes
Fillable fields55
Avg. time to fill out10 min
Edition4/25
Issuing agencyFood and Drug Administration
Where to sendThe sponsor; investigators should not send this form directly to the Food and Drug Administration
Matches the agency's fileYes, checked October 2, 2026
Other namesForm FDA 1572, FDA 1572, FDA Form 1572, 1572, 1572 form, Statement of Investigator
Official sourceForm FDA 1572 (Rev 4/25), Food and Drug Administration